PHAR Pharming Group N.V.
Healthcare$12.60-1.64%ClosedMarket Cap: $889.9M
As of 2026-05-25
Valuation
P/E (TTM)
386.59
PEG
3.12
P/B
3.83
P/S
2.65
EV/EBITDA
30.85
DCF Value
$12.10
FCF Yield
5.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
88.1%
Operating Margin
6.4%
Net Margin
3.4%
ROE
4.7%
ROA
2.5%
ROIC
3.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $72.7M | 90.8% | $2.5M | $-5.2M | $— | — |
| Q4 null | $106.50B | 80.2% | $2.00B | $5.30B | $— | — |
| FY null | $377.2M | 87.9% | $19.4M | $2.9M | $— | — |
| Q3 null | $97.3M | 92.7% | $15.8M | $7.5M | $— | — |
| Q2 null | $93.2M | 90.4% | $10.8M | $4.7M | $— | — |
| Q1 null | $79.1M | 89.5% | $-7.0M | $-14.7M | $— | — |
| Q4 null | $92.7M | 86.8% | $6.7M | $2.9M | $— | — |
| FY null | $297.2M | 88.1% | $-8.6M | $-11.8M | $— | — |
| Q3 null | $74.8M | 90.9% | $4.1M | $-1.0M | $— | — |
| Q2 null | $74.0M | 89.2% | $-4.0M | $-1.2M | $— | — |
| Q1 null | $55.6M | 84.9% | $-16.3M | $-12.4M | $— | — |
| Q4 2023 | $81.2M | 91.2% | $1.1M | $-3.1M | $-0.03 | — |